PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
oleh: Pottayil G. Sasikumar, Naremaddepalli S. Sudarshan, Srinivas Adurthi, Raghuveer K. Ramachandra, Dodderi S. Samiulla, Anirudha Lakshminarasimhan, Anuradha Ramanathan, Talapaneni Chandrasekhar, Amit A. Dhudashiya, Sumalatha R. Talapati, Nagesh Gowda, Sreenivasulareddy Palakolanu, Jiju Mani, Bandi Srinivasrao, David Joseph, Nigam Kumar, Rashmi Nair, Hanudatta S. Atreya, Nagaraj Gowda, Murali Ramachandra
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2021-06-01 |
Deskripsi
Sasikumar et al. describe the identification and characterization of CA-170, a small molecule inhibitor of PD-L1 and VISTA. They find that CA-170 activates T cells and exhibits anti-tumor efficacy in mouse models. This study highlights the potential of CA-170, which has advanced to human clinical trials, as an anti-cancer drug.